Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats only CCR5‑tropic human immunodeficiency virus type 1 (HIV‑1) infection. Sold as Selzentry. Every FDA application for this active ingredient: 2 branded and 5 generic.
As of Nov 15, 2026, FDA lists 7 applications for Maraviroc (sold as Selzentry), first approved Aug 6, 2007, with 6 new uses approved and 0 published complete response letters.
First approved: Aug 6, 2007
Applications: 7
New uses approved: 6
Complete response letters: 0
Medicare spending, 2025: $18.9M
First approved in the EU: Sep 18, 2007
First approved in Japan: Dec 25, 2008
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Maraviroc
Part D
$16.0M
-14%
1,619
Selzentry
Part D
$2.9M
-30%
205
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
MARAVIROC 150 MG TABLET: $8.29 per unitGeneric · -9% in a year
MARAVIROC 300 MG TABLET: $6.36 per unitGeneric · -37% in a year
SELZENTRY 150 MG TABLET: $28.02 per unitBrand · +0% in a year
SELZENTRY 300 MG TABLET: $28.13 per unitBrand · +0% in a year
Approvals in the EU (EMA)
First approved in the EU 1 month after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
First approved in Japan 17 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Celsentri, new ingredientA drug containing a new active ingredient indicated for the treatment of CCR5-tropic HIV-1 infection. · Pfizer Japan Inc. · Dec 25, 2008
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
